PMID- 33067724
OWN - NLM
STAT- MEDLINE
DCOM- 20210401
LR  - 20210401
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
VI  - 58
IP  - 3
DP  - 2021 Mar
TI  - Health utility of type 2 diabetes patients using basal insulin in China: results 
      from the BEYOND II study.
PG  - 329-339
LID - 10.1007/s00592-020-01618-1 [doi]
AB  - OBJECTIVE: To derive the health utility scores of type 2 diabetes (T2D) patients 
      using basal insulin (BI) with diverse characteristics in China. METHODS: The 
      study used the data of insulin-using T2D patients on BI treatment enrolled in the 
      BEYOND II study, which is a multi-center, observational study from 78 hospitals 
      nationwide. The 3-level EQ-5D (EQ-5D-3L) questionnaire was administered to each 
      patient to derive their health utility scores using the EQ-5D-3L value set for 
      China. Patients' clinical and sociodemographic information were retrieved from 
      their electronic case report form (eCRF). Ordinary least-square models with 
      different specifications were explored to identify the best-fitting model to 
      predict the utility scores. RESULTS: The sample (n = 12,583) achieved a mean 
      (standard deviation) EQ-5D-3L utility score of 0.936 (0.120). According to the 
      model, a Chinese male who was younger than 59 years, not underweight, diagnosed 
      with T2D shorter than 10 years, with controlled plasma glucose and free of 
      diabetes complications/comorbidities, would have a mean utility of 0.993. Being 
      female, older age, underweight, and higher plasma glucose, longer diabetes 
      duration was negatively related to EQ-5D-3L scores. Comorbidities and seven of 
      eleven complications were associated with utility decrement. Interactions between 
      some complications were also discovered. CONCLUSIONS: The derived health utility 
      scores for diabetes complications could facilitate the assessment of the 
      cost-effectiveness of health interventions for Chinese insulin-using T2D 
      patients.
FAU - Li, Chaoyun
AU  - Li C
AD  - Health Economics and Outcome Research, Sanofi, Shanghai, China.
FAU - Zhou, HuiJun
AU  - Zhou H
AD  - Department of Public AdministrationBusiness School, University of Shanghai for 
      Science and Technology, Shanghai, China.
FAU - Wang, Pei
AU  - Wang P
AUID- ORCID: 0000-0003-3661-3944
AD  - School of Public Health, Fudan University, 130 Dong An Road, Shanghai, 200032, 
      China. wang_p@fudan.edu.cn.
AD  - Key Lab of Health Technology Assessment, National Health Commission of the 
      People's Republic of China (Fudan University), Shanghai, China. 
      wang_p@fudan.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20201017
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Insulins)
SB  - IM
MH  - Adult
MH  - Aged
MH  - China/epidemiology
MH  - Comorbidity
MH  - Cost-Benefit Analysis
MH  - Diabetes Complications/economics/epidemiology/therapy
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/economics/*epidemiology
MH  - Female
MH  - Health Care Costs/statistics & numerical data
MH  - Health Resources/*statistics & numerical data
MH  - Health Status
MH  - Humans
MH  - Insulins/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Quality of Life
MH  - Research Design
MH  - Surveys and Questionnaires
OTO - NOTNLM
OT  - Complications
OT  - EQ-5D
OT  - Insulin
OT  - Type 2 diabetes
OT  - Utility
EDAT- 2020/10/18 06:00
MHDA- 2021/04/02 06:00
CRDT- 2020/10/17 05:30
PHST- 2020/07/29 00:00 [received]
PHST- 2020/10/05 00:00 [accepted]
PHST- 2020/10/18 06:00 [pubmed]
PHST- 2021/04/02 06:00 [medline]
PHST- 2020/10/17 05:30 [entrez]
AID - 10.1007/s00592-020-01618-1 [pii]
AID - 10.1007/s00592-020-01618-1 [doi]
PST - ppublish
SO  - Acta Diabetol. 2021 Mar;58(3):329-339. doi: 10.1007/s00592-020-01618-1. Epub 2020 
      Oct 17.